공간 유전체학 및 전사체학 시장 : 예측(2026-2031년)

Spatial Genomics And Transcriptomics Market is forecasted to rise at a 11.87% CAGR, reaching USD 1435.83 million in 2031 from USD 732.413 million in 2025.

The spatial genomics and transcriptomics market is expanding rapidly, driven by surging demand for technologies enabling precision medicine and targeted therapy development. Academic institutions are integrating these tools into disease research programs for deeper insights into cellular heterogeneity. Researchers are leveraging high-resolution spatial mapping to dissect tumor microenvironments and tissue architecture. Biotech firms are introducing advanced sequencing platforms supporting single-cell and tissue-scale analysis.

Spatial genomics and transcriptomics technologies facilitate the visualization and analysis of gene expression patterns within intact tissue contexts, preserving spatial organization lost in traditional bulk sequencing. These approaches combine genomic or transcriptomic profiling with morphological data, revealing cellular interactions, heterogeneity, and microenvironmental influences critical for understanding disease progression and therapeutic response. The market is growing robustly, fueled by applications in oncology, neurology, immunology, and developmental biology, where spatial context enhances biomarker discovery, diagnostic accuracy, and drug target identification.

Key growth drivers include escalating applications in drug discovery and development, particularly for cancer and neurological disorders, where spatial profiling elucidates complex pathologies and informs targeted interventions. Increasing research in genomics and transcriptomics, supported by initiatives like the Human Cell Atlas, amplifies adoption in academic settings for studying genetically derived diseases. Widespread use in academic facilities provides comprehensive morphological and molecular analyses across diverse conditions. Rising adoption of transcriptomics for single-cell resolution, aided by techniques like laser capture microdissection, addresses tissue heterogeneity and enables archival spatial data preservation.

Geographically, North America is predicted to hold a significant share, attributed to strategic investments in pathology research, emphasis on transcriptomics R&D, and robust infrastructure supporting high-throughput sequencing and spatial resolution advancements.

Prominent products include 10x Genomics' Visium Spatial Gene Expression, which maps whole-transcriptome profiles with morphological context in fresh frozen or FFPE tissues for insights into development, pathology, and translational studies. NanoString Technologies' GeoMx Digital Spatial Profiler enables spatial transcriptomics and proteomics from single slides, offering flexibility from discovery to translational workflows.

Leading companies include Natera Inc., 10x Genomics, Dovetail Genomics, Illumina, Inc., and S2 Genomics, Inc. These entities advance platforms integrating next-generation sequencing, imaging, and bioinformatics for high-plex, high-resolution spatial profiling.

Overall, the market is advancing steadily, positioned to revolutionize disease understanding through preserved tissue context, accelerating precision diagnostics and therapeutics amid rising chronic disease complexity and research intensity.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Spatial Genomics and Transcriptomics Market Segmentation

• By Type
• Spatial Genomics
• In-Situ Hybridization
• Next-Generation Sequencing
• Others
• Spatial Transcriptomics
• Sequencing-Based
• Probe-Based
• Imaging-Based
• By Application
• Neurology
• Oncology
• Immunology
• Developmental Biology
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Spatial Genomics
  • 5.2.1. In-Situ Hybridization
  • 5.2.2. Next-Generation Sequencing
  • 5.2.3. Others
• 5.3. Spatial Transcriptomics
  • 5.3.1. Sequencing-Based
  • 5.3.2. Probe-Based
  • 5.3.3. Imaging-Based

6. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Neurology
• 6.3. Oncology
• 6.4. Immunology
• 6.5. Developmental Biology
• 6.6. Others

7. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. 10x Genomics
• 10.2. Illumina, Inc.
• 10.3. S2 Genomics, Inc.
• 10.4. Bruker Spatial Biology, Inc.
• 10.5. Velsera
• 10.6. Bio-Techne
• 10.7. Akoya Biosciences
• 10.8. Standard BioTools
• 10.9. Vizgen Inc.
• 10.10. Agilent Technologies, Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations